Please login to the form below

Not currently logged in

UCB strikes new Middle East and African sales deal for key products

Drops the RX Group to partner with NewBridge Pharmaceuticals

UCB sign

UCB has picked up a new commercial partner for three of its key products in the Middle East and Africa, striking a deal with NewBridge Pharmaceuticals and dropping former partner the Rx Group.

The deal covers the Belgium biopharmaceutical firm's Cimzia (certolizumab pegol) for Crohn's disease and rheumatoid arthritis, Vimpat (lacosamide) for epilepsy and Neupro (rotigotine) for Parkinson's disease and restless legs syndrome.

The three drugs achieved 45 per cent growth in global sales that came to €413m for the first half of this year and UCB has ambitions for the trio of treatments to reach more than 1.5 million patients.

Its head of international major markets Luc Vermeesch said: “Within UCB we are passionate about enabling families with severe diseases to enjoy normal, everyday lives.

“To reach this objective we are thrilled to be working with NewBridge Pharmaceuticals, and rely on their solid experience and strong leadership team in the Middle East and Africa region.”

Through the deal NewBridge will acquire local rights to UCB's three key drugs and will be responsible for managing the local regulatory approval process, future commercialisation, and pharmacovigilance for several Middle East and African countries.

Joe Henein, president and CEO of NewBridge, said: “This transaction represents a major milestone for NewBridge as we execute on our high growth strategy to provide access to innovative therapeutics in our core markets of the Middle East and Africa.

“We strongly believe that Cimzia, Vimpat and Neupro have great potential in our territory and will contribute significantly to the physicians' abilities to treat patients with immunologic and CNS afflictions respectively, thereby improving quality of life for these patients.”

Dubai-based NewBridge Pharmaceuticals is a specialty therapeutics company that focuses on commercialising pharmaceutical, biologic, diagnostic and medical device products across the AfMET markets (Africa, Middle East, Turkey & Caspian regions).

The firm was set up last year to specialise in in-licensing, acquiring, registering and commercialising therapeutics approved by regulators in the US, Europe and Japan.

22nd November 2012

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....